Type 1 Diabetes TrialNet
Study Participants Healthcare Professionals Researchers Locations Publications What is TrialNet? News and Events Get Screened! Home

Information for Study Participants

Anti IL-1Beta (Canakinumab) in Recent Onset Diabetes

Status: No Longer Recruiting

Eligibility Criteria

You can be screened for this study if:

  • You are 6 to 45 years old


  • You were diagnosed with type 1 diabetes less than 3 months ago (There are other eligibility criteria which are considered at the screening visit).

About this Study

Type 1 diabetes is an autoimmune disease. This means that your immune system, the part of the body that helps fight infections, mistakenly attacked the cells in your body that produced insulin. These cells, called beta cells, are found in your pancreas.

This attack probably started years ago. Once many of your beta cells were damaged, your blood glucose levels went too high, and you had to start taking insulin by injection.

At this point, when you have had diabetes for less than three months, you may have beta cells left that produce some insulin. People who continue to make a little insulin may have fewer problems with low blood glucose (hypoglycemia). They may also have an easier time keeping their blood glucose levels in the normal range. This lowers the risk of the long-term complications of diabetes.

Right now, there is no proven treatment that will protect the remaining beta cells. In type 1 diabetes, the body's immune system keeps destroying them. By a few years after diagnosis, most people with type 1 diabetes are making no insulin of their own.

In this study, we are testing whether repeated injections of an experimental medication called canakinumab will help people with newly-diagnosed type 1 diabetes continue to make some of their own insulin. In this study, we will compare the progression of diabetes in people who get injections of canakinumab with those who get injections that look the same but have no canakinumab, called placebo injections.

What will I be asked to do?

Two-thirds of the people in this study will get injections of canakinumab. They are in the treatment group.

One third of the people in this study will get injections that look like canakinumab but have no active drug. This is called a placebo injection. The people getting the placebo injections are in the control group.

Both groups will get 12 injections over one year with an injection occurring once a month. You will be asked to return for additional visits for up to three years after completing the injections.

You can't choose your group. A computer will choose your group for you. It's by chance, like drawing straws. This is called random assignment, or randomization.

This study is double-masked. While the study is going on, neither you nor your study team will know if you're in the treatment group or the control group. At the end of the study, we will tell you whether you were in the treatment group or the control group.

As a research volunteer, you can decide to stop being in this study at any time. We hope that you will stay in the study. You will be helping us learn more about how to help people with diabetes.


To see if you might be eligible for this study and for a referral to a TrialNet site:

The blood test to determine whether or not you are at risk for Type 1 Diabetes is part of the Natural History study. Please see the list of Clinical Centers for more information.

Information will be kept confidential.

Back To Top